Robert Graham Ph.D. Hybrid Medical Media Reporting From New York City New York Wall Street
What is the Score of The Carl Jung Myers-Briggs Type Indicator (MBTI) For Your Breast Cancer Patients.
What is the Result of The Carl Jung Myers-Briggs Type Indicator (MBTI) For Your Breast
Cancer Patients. Myers-Briggs Type Indicator (MBTI) assessment is a psychometric questionnaire designed to measure psychological preferences in how people perceive the world and make decisions.
Now that it is clear that a genomic test for a breast cancer patient will provide data for patients and their families to make decision on positive breast cancer genomics test. Genomics begin with the provision of the human genome sequence in 20001 set in motion several waves of cancer research. The identification of an essentially complete set of protein-coding genes, coupled with the discovery of novel transcribed elements such as microRNAs (see the Glossary), has fostered an explosion of investigation using array-based approaches into patterns of gene expression in most cancer types.
Brought To You By gloStream Similarly, the development of systematic approaches to identify somatic mutations has prompted exhaustive analyses of changes in cancer genomes, including copy-number changes (deletions and amplifications of DNA), rearrangements, small insertions and deletions, and point mutations.2 Recently, these efforts have culminated in the sequencing of complete genomes of human cancers, providing comprehensive catalogues of
somatic mutations.3,4 These studies have yielded insights into the genes that contribute to cellular transformation.2 In parallel, the characterization of inherited variation in human populations has unleashed a surge of exploration into cancer susceptibility, focusing mainly on DNA variants that are common in the general population and that confer small increases in cancer risk. Finally, sets of biologic reagents have been developed that interfere with the function of essentially all genes in living cells, the most widely used being small interfering RNAs. These are being used in myriad ways — for example, to systematically determine which genes are required for cancer cells to survive and which genes confer sensitivity to particular drugs.
Gennxeix analytics have shown that breast cancer patients psyche is important when treating the patients cancer. The Patients ego also plays and important role in the elimination of breast cancer. Carl Jung divided the human psyche divided into 3 parts: the ego, the personal unconscious, and the collective unconscious. He is particularly known for his identification of the latter. Jung characterizes these as essentially descending levels of our psyche. The ego is the conscious and thinking self; the personal unconscious is the collective personal experiences unique to each individual, and the collective unconscious is a collection of experiences and behavior patterns that is common to all people.
The common experience of practicing oncologists is that only a subgroup of patients with a specific type of breast cancer will derive substantial benefit from a particular therapy. Differences in responses to the same treatment among patients are unsurprising in light of the substantial genomic heterogeneity that exists among tumors. Some of these genomic differences have an important role in determining the likelihood of a clinical
response to treatment. Notably, in instances in which the therapeutic agent is targeted at a particular cellular protein, genomic alterations in the gene encoding that protein can be major determinants of response. For example, overexpression and amplification of HER2 in breast cancer is a strong predictor of benefit from treatment with trastuzumab, an antibody directed against HER2.17 On the basis of such findings, the FDA approved trastuzumab in 1998 for use in the treatment of HER2-amplified metastatic breast cancer.
Following this and other examples, most new agents entering clinical trials over the past decade have been postulated to influence pathways important for the proliferation or survival of cancer cells. The genes involved in these cellular pathways are frequently mutated as a consequence of somatic alterations (point mutations, deletions, amplifications, and translocations) known as driver mutations, which directly contribute to the abnormal growth of the cancer cell. As a result, the presence or absence of mutations within these genes can have a profound effect on a patient's response to a specific targeted therapy.
To take advantage of the full array of options physicians now have with genomics it important that your breast cancer doctors have EMR Electronic Health Records to capture a patients Carl Jung Myers-Briggs Type Indicator (MBTI) scores and provide the breast cancer patient with the best possible care.
Gennxeix Biotech has identify which of the breast cancer gene products and molecular mechanisms that are implicated by sequencing Genomics education for most health care providers is inadequate, and because of the fast-moving nature of the field, there is a paucity of evidence-based guidelines and resources for the vast majority of genomic interventions. Current paradigms for providing genetic services, which were developed to handle rare chromosomal and monogenic conditions, break down in the setting of genomic approaches to more common and etiologically complex conditions.
No comments:
Post a Comment